Brazil's public health system, the Sistema Único de Saúde (SUS), is now offering free genetic tests to identify hereditary risks of breast cancer [1].
This expansion into precision medicine aims to reduce mortality rates by identifying high-risk patients before cancer develops. The move follows a concerning trend of rising deaths from the disease in specific regions of the country.
The health ministry approved the inclusion of next-generation sequencing (NGS) in the SUS portfolio on April 10, 2026 [4]. This advanced diagnostic tool allows clinicians to pinpoint specific genetic mutations that increase a woman's likelihood of developing breast cancer [2]. The official announcement regarding the rollout of these tests occurred in mid-May 2026 [3].
The decision to integrate NGS into the national health system was driven by critical public health data. In Rio Grande do Norte, for example, breast-cancer deaths increased by 22.8% [5]. By providing these tests for free, the government intends to scale preventive screenings, and personalized treatment plans for those with a proven hereditary predisposition [1].
Under the new guidelines, the tests are available nationwide through the SUS network [1]. The use of NGS represents a shift toward more sophisticated diagnostics in the public sector—moving away from broader screenings toward targeted genetic analysis [4].
Medical professionals expect the tests to help women make informed decisions about prophylactic surgeries or more frequent surveillance. The availability of these tests in the public system removes a significant financial barrier, as genetic sequencing has historically been available primarily in private clinics [4].
“The public health system will use next-generation sequencing to identify hereditary mutations.”
The integration of next-generation sequencing into Brazil's SUS marks a significant shift toward precision medicine in one of the world's largest public health systems. By transitioning from reactive treatment to proactive genetic screening, Brazil is attempting to curb rising mortality rates through early intervention. This move suggests a broader strategy to democratize high-cost medical technology, ensuring that hereditary risk assessment is not limited to wealthy citizens.
